Ainos, Inc. AIMD
We take great care to ensure that the data presented and summarized in this overview for Ainos, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AIMD
Top Purchases
Top Sells
About AIMD
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Insider Transactions at AIMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2025
|
Chung Jung Tsai Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.72%
|
$0
$0.5 P/Share
|
|
Jun 25
2025
|
Chung Jung Tsai Director |
SELL
Open market or private sale
|
Direct |
7,000
-0.5%
|
$0
$0.5 P/Share
|
|
Jun 25
2025
|
Ting Chuan Lee Director |
SELL
Open market or private sale
|
Direct |
2,894
-0.2%
|
$0
$0.51 P/Share
|
|
Jun 23
2025
|
Taiwan Carbon Nano Technology Corp > 10% Shareholder |
BUY
Open market or private sale
|
Direct |
29,476
+0.54%
|
-
|
|
Jun 23
2025
|
Ase Test, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
29,476
+33.36%
|
-
|
|
Jun 23
2025
|
Chung Jung Tsai Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.71%
|
$0
$0.5 P/Share
|
|
Jun 19
2025
|
Chung Jung Tsai Director |
SELL
Open market or private sale
|
Direct |
10,903
-0.77%
|
$0
$0.55 P/Share
|
|
Jun 18
2025
|
Chung Jung Tsai Director |
SELL
Open market or private sale
|
Direct |
5,000
-0.35%
|
$0
$0.52 P/Share
|
|
Apr 08
2025
|
Chung Jung Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
900,000
+38.66%
|
$0
$0.48 P/Share
|
|
Apr 08
2025
|
Chun Hsien Tsai CEO, PRESIDENT, CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
900,000
+35.27%
|
$0
$0.48 P/Share
|
|
Apr 08
2025
|
Ting Chuan Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
900,000
+38.6%
|
$0
$0.48 P/Share
|
|
Mar 10
2025
|
Chung Yi Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.33%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Chun Hsien Tsai CEO, PRESIDENT, CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+21.01%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Ting Chuan Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+27.34%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Pao Sheng Wei Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.33%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Yao Chung Chiang Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.09%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Hsin Liang Christopher Lee CFO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+47.49%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Wen Han Chang Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+36.79%
|
$0
$0.46 P/Share
|
|
Mar 10
2025
|
Chung Jung Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+27.48%
|
$0
$0.46 P/Share
|
|
Jan 31
2025
|
Pao Sheng Wei Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,468
+2.63%
|
$0
$0.68 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 4.96M shares |
|---|---|
| Open market or private purchase | 29.5K shares |
| Open market or private sale | 29.5K shares |
| Open market or private sale | 45.8K shares |
|---|